Back to results
US 2023/0265187 A1Published application
Anti-tigit antibody and methods of use thereof
AssigneeCrystal Bioscience Inc.
InventorsEllen COLLARINI, Shelley IZQUIERDO, Christel IFFLAND, William Don HARRIMAN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. For example, the antibody may be used to treat a patient for cancer, particularly a patient is also being treated or has been treated with an immune checkpoint inhibitor, e.g., a PD-1/PD-L1 inhibitor.
Claims21
An antibody that binds to TIGIT, wherein the antibody comprises:
- (a) a variable domain comprising:
- i. heavy chain CDR1, CDR2 and CDR3 regions that are identical to the heavy chain CDR1, CDR2 and CDR3 regions of an antibody selected from FIG. 1;
- and
- ii. light chain CDR1, CDR2 and CDR3 regions that are identical to the light chain CDR1, CDR2 and CDR3 regions of the antibody, selected from FIG. 2;
- or
- (b) a variant of said variable domain of (a) that is otherwise identical to said antibody variable domain except for up to 10 amino acid substitutions in the collective CDR regions of the variable domain of (a).
3 more elements
Dependencies are inferred from the claim text.